✦ LIBER ✦

Follow-up studies on the immune status of patients with Hodgkin's disease after splenectomy and treatment, in relapse and remission

✍ Scribed by Hancock, B W; Bruce, L; Dunsmore, I R; Ward, A M; Richmond, J

Book ID: 109833631
Publisher: Nature Publishing Group
Year: 1977
Tongue: English
Weight: 975 KB
Volume: 36
Category: Article
ISSN: 0007-0920
DOI: 10.1038/bjc.1977.199

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A prospective study of the changes in th

A prospective study of the changes in the immune status before, during, and after multiple-agent chemotherapy for Hodgkin's disease

✍ Ruud E. N. van Rijswijk; J. P. H. Bob Sybesma; Louis Kater 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 735 KB

The remission status before and the PCR

The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin’s lymphoma

✍ Moos, M; Schulz, R; Martin, S; Benner, A; Haas, R 📂 Article 📅 1998 🏛 Nature Publishing Group 🌐 English ⚖ 135 KB

The impact of treatment of depression on

The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease

✍ Matthew Menza; Roseanne DeFronzo Dobkin; Humberto Marin; Margery H. Mark; Michae 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 318 KB 👁 1 views

## Abstract Parkinson's disease (PD) is a common neurodegenerative disease affecting up to one million individuals in the United States. Depression is found in 40 to 50% of these patients and is associated with a variety of poor outcomes for both patients and their families. Despite this, there are

Intravenous corticotrophin vs. Hydrocort

Intravenous corticotrophin vs. Hydrocortisone in the treatment of hospitalized patients with Crohn's disease: A randomized double-blind study and follow-up

✍ Alexander Chun; Ron M. Chadi; Dr. Burton I. Korelitz; Thomas Colonna; Joseph B. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 487 KB 👁 2 views

Serum CA 125 is of clinical value in the

Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma : Correlation with tumor parameters and disease activity

✍ Ikram A. Burney; Tariq Siddiqui; Imran Siddiqui 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 30 KB 👁 3 views

W e read with interest the article published in Cancer earlier this year regarding the elevation of CA 125 in patients with non-Hodgkin's lymphoma and its normalization with clinical response. 1 Earlier a case report had also emerged about elevation of CA 125 in a patient within tuberculous peritoni

Serum CA 125 is of clinical value in the

Serum CA 125 is of clinical value in the staging and follow-up of patients with non-hodgkin's lymphoma : Correlation with tumor parameters and disease activity

✍ Mario Lazzarino; Ester Orlandi; Catherine Klersy; Cesare Astori; Ercole Brusamol 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB 👁 3 views

## Background: Ca 125 is a glycoprotein produced by epithelial ovarian tumors and by mesothelial cells; its levels also have been shown to be elevated in patients with non-hodgkin's lymphoma (nhl). ## Methods: The authors evaluated serum ca 125 levels in patients with nhl to elucidate the frequen